RayzeBio to Build Radiopharmaceutical Manufacturing Plant in Indiana
RayzeBio, a Bristol Myers Squibb company, is investing over $173 million to establish a new 450,000-square-foot radiopharmaceutical cancer therapy manufacturing plant in Whitestown, Indiana, and create up to 100 new jobs.
Indianapolis, IN, August 27, 2026 — RayzeBio, a company operating under Bristol Myers Squibb, has announced plans to construct a significant new manufacturing facility in Whitestown, Indiana. The investment for this project is reported to be over $173 million.
The planned facility will span 450,000 square feet and is designated for the manufacturing of radiopharmaceutical cancer therapies. Radiopharmaceuticals are a class of drugs that use radioactive compounds to target and treat cancer.
The establishment of this plant is expected to generate up to 100 new job opportunities in the Whitestown area. The specific timeline for the construction and operational launch of the facility was not provided in the announcement.
This development marks a notable expansion for RayzeBio within the growing field of targeted cancer treatments. The company’s focus on radiopharmaceuticals aligns with a broader industry trend towards developing precision medicines designed to deliver radiation directly to cancer cells, potentially minimizing damage to surrounding healthy tissue.
The location in Whitestown, Indiana, was selected for the development. Further details regarding the project’s phases, including construction commencement and anticipated completion dates, have not yet been disclosed.
Story summarized from the original created by John Herrick on www.wrtv.com, see more information here.
